Avastin for ependymoma – pro
Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies, that can recurr in the spinal cord. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. There are several ongoing trials in different combination but not with Temodar: http://clinicaltrials.gov/ct2/results?term=avastin++ependymoma+.
At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor. In recurrent glioblastoma, encouraging responses with bevacizumab have been observed but the optimal combination is not defined and there are no phase III trials.
R. M. Green, T. Cloughesy, R. Stupp, L. M. DeAngelis, E. A. Woyshner, D. E. Ney, A. B. Lassman; Kaiser Foundation Hospital, Los Angeles, CA Bevacizumab for recurrent ependymoma. J Clin Oncol 27:15s, 2009 (suppl; abstr 2060)
Green, R. M., Cloughesy, T. F., Stupp, R., DeAngelis, L. M., Woyshner, E. A., Ney, D. E., Lassman, A. B.
Bevacizumab for recurrent ependymoma
Neurology 2009 73: 1677-1680